Minovlar
- Minovlar
- Ovcon (Salt/Mix)
- Neocon (Salt/Mix)
- Binovum (Salt/Mix)
- Modicon (Salt/Mix)
- Create:2006-04-28
- Modify:2025-01-04
- Minovlar
- Ovcon (Salt/Mix)
- Neocon (Salt/Mix)
- Binovum (Salt/Mix)
- Modicon (Salt/Mix)
- Noriday (Salt/Mix)
- Brevicon (Salt/Mix)
- Brevinor (Salt/Mix)
- Synphase (Salt/Mix)
- Nora-BE (Salt/Mix)
- Nor-Q.D.
- Tri-Norinyl (Salt/Mix)
- component of Norimin (Salt/Mix)
- component of Ovysmen (Salt/Mix)
- Norethin 1/35 E (Salt/Mix)
- Ortho-novum 1/35 (Salt/Mix)
- Ortho-novum 1/50 (Salt/Mix)
- component of Trinovum (Salt/Mix)
- Ortho-novum 7/7/7 (Salt/Mix)
- 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)-
- component of Norinyl-1 (Salt/Mix)
- component of Norquentiel (Salt/Mix)
- component of Neocon 1/35 (Salt/Mix)
- component of Norinyl 1-35 (Salt/Mix)
- 17-Ethynyl-17-hydroxyestr-4-en-3-one #
- 17.alpha.-Ethynyl-17-hydroxyest-4-en-3-one
- 17.alpha.-Ethynyl-3-oxo-4-estren-17.beta.-ol
- 4-Estren-17.alpha.-ethynyl-17.beta.-ol-3-one
- 17.beta.-Hydroxy-17.alpha.-ethynylestr-4-en-3-one
- 17-.alpha.-Ethynyl-17-.beta.-hydroxy-4-estren-3-one
- 17-Hydroxy-17-.alpha.-19-norpregn-4-en-20-yn-3-one
- (17-.alpha.)-17-Hydroxy-19-norpregn-4-en-20-yn-3-one
- 17-.alpha.-19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-
- 19-Norandrost-4-en-3-one, 17.alpha.-ethynyl-17.beta.-hydroxy-
- VIKNJXKGJWUCNN-NSDIEPNESA-N
- ENT
- NET
IMAP assessments - 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)-: Human health tier I assessment
IMAP assessments - 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)-: Environment tier I assessment
◉ Summary of Use during Lactation
This record contains information specific to oral norethindrone used alone for contraception. Those with an interest in a combination oral contraceptive should consult the record entitled, Contraceptives, Oral, Combined. No information is available on the use of high-dose norethindrone acetate during breastfeeding.
Although nonhormonal methods are preferred during breastfeeding, progestin-only contraceptives such as norethindrone are considered the hormonal contraceptives of choice during lactation. Fair quality evidence indicates that norethindrone does not adversely affect the composition of milk, the growth and development of the infant or the milk supply. Some evidence indicates that progestin-only contraceptives may offer protection against bone mineral density loss during lactation, or at least do not exacerbate it. A large percentage of women who planned to breastfeed discontinued oral progestin-only contraceptives by 3 months postpartum and progestin-only contraceptives often result in rapid repeat pregnancy.
◉ Effects in Breastfed Infants
No consistent physical, mental, or radiologic differences have been found in infants whose mothers were using norethindrone enanthate (Norplant). Some studies found increased infant weight gain among the infants of treated women.
A short-term study of 12 women who received oral norethindrone 350 mcg daily starting 48 hours postpartum found no differences in infant weight gain over 14 days compared to 8 women taking a placebo.
◉ Effects on Lactation and Breastmilk
Studies of varying size and quality on the use of long-acting norethindrone injections (acetate or enanthate) have found that the use of levonorgestrel implants (Norplant or Norplant-2) as a contraceptive beginning at 6 weeks postpartum or later either has no clinically important negative effect on the quality of breastmilk and results in either no effect or an increase in the milk supply and duration of lactation. In one study, women who received the implant at 6 days postpartum, a transient decrease in milk protein occurred 2 weeks after implant insertion. A decrease in milk phosphorus content was also observed between 2 and 4 months after implant insertion in this group and at 3 months postpartum, the early insertion group had a higher rate of supplementation. In another study, women given norethindrone enanthate depot injection less than 48 hours postpartum were 2.5 to 3 times more likely to have postpartum depression at 6 weeks postpartum. No differences were seen at 1 and 12 weeks postpartum.
A short-term study of 12 women who received oral norethindrone 350 mcg daily starting 48 hours postpartum found no differences in milk production or milk composition over 14 days compared to 8 women taking a placebo.
One small, nonrandomized study found that oral norethindrone 350 mcg daily decreased the quantity and quality (lower protein, lipids and calcium) compared to controls who received nonhormonal contraception.
In a nonrandomized, nonblinded study comparing women who were breastfeeding at discharge, 102 postpartum women received depot medroxyprogesterone acetate (dosage not stated) in the early postpartum period (average 51.9 hours postpartum; range 6.25 to 132 hours), 181 received another progestin-only contraceptive and 138 used nonhormonal contraception. No differences in breastfeeding rates were seen at 2 and 6 weeks, but women receiving any hormonal contraceptive were breastfeeding at a lower rate (72.1% vs 77.6%) at 4 weeks postpartum. The authors concluded that progestin-only contraception initiated in the early postpartum period had no adverse effects on breastfeeding rates.
A study analyzed data from a prospective cohort study of U.S. women from May 2005 through June 2007. Women were followed from the third trimester of pregnancy throughout the first year postpartum. Data from the subset of women who intended to breastfeed for 3 months or longer postpartum during their third trimester of pregnancy and who were using a contraceptive at 3 months postpartum were analyzed (n = 1349). Women who intended to breastfeed for at least 4 months and were taking a progestin-only oral contraceptive, such as norethindrone, were 3.15 times more likely to be breastfeeding (exclusive or nonexclusive) at 4 months than women who used a nonhormonal contraceptive. Women who said they would breastfeed for 3 to 4 months had 4-month breastfeeding rates equivalent to those using a nonhormonal contraceptive. These rates were much higher than those of women who were taking an estrogen-containing, combined oral contraceptive.
- Australian Industrial Chemicals Introduction Scheme (AICIS)19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)-https://services.industrialchemicals.gov.au/search-assessments/
- New Zealand Environmental Protection Authority (EPA)LICENSEThis work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International licence.https://www.epa.govt.nz/about-this-site/general-copyright-statement/
- Drugs and Lactation Database (LactMed)Norethindronehttps://www.ncbi.nlm.nih.gov/books/n/lactmed/LM419/
- NIST Mass Spectrometry Data CenterLICENSEData covered by the Standard Reference Data Act of 1968 as amended.https://www.nist.gov/srd/public-lawNorethindronehttp://www.nist.gov/srd/nist1a.cfm
- PubChem